Menu

Lasker Awards Recognize Work on Histones, Anesthesia, RNA

This year’s winners are C. David Allis, Michael Grunstein, John Glen, and Joan Steitz.

Sep 11, 2018
Shawna Williams
From left to right: C. David Allis, Michael Grunstein, John Glen, and Joan Steitz
ALBERT AND MARY LASKER FOUNDATION

The winners of this year’s Lasker Awards are C. David Allis of Rockefeller University and Michael Grunstein of the University of California, Los Angeles, for discoveries about the proteins that package DNA; John “Iain” Glen, formerly a pharmaceutical researcher at AstraZeneca, for developing the drug propofol; and Yale University’s Joan Steitz for leadership and research throughout her career, the Lasker Foundation announced today (September 11). The Laskers, prestigious awards often used to forecast future Nobel Prize winners, each come with a cash prize of $250,000.

At one time, Grunstein recalled in a teleconference with the media today, most researchers assumed that because the histone proteins that package DNA are highly conserved among vastly different species, they must not be very interesting. But in the 1980s, “we found that they’re very important, not only as packing material, but as proteins that regulate gene activity,” he says. 

Allis and colleagues would later uncover more details about how this regulation works, including an enzyme that removes acetyl tags on histones, changing genes’ expression levels. The work helped lay the foundation for developing drugs for cancer and other conditions that involve aberrant histone tags.

See “Support for Histone Code?

In an interview with Science, Glen, a former veterinarian, recalls how it took 13 years to develop propofol, now one of the world’s most-used anesthetics. “I remember knowing it was special when I saw how quickly the animals recovered after they woke up,” he tells the magazine. “A whole pen of pigs could be out cold one moment, and then digging into their food the next.”

Steitz’s award recognizes not a specific achievement, but her “four decades of leadership in biomedical science,” according to the Lasker’s statement. She is known for her discovery that small nuclear ribonucleoproteins (snRNPs) are key players in splicing finished mRNA transcripts within cells, and for other RNA-related work. 

She has also been an advocate for women in science. “When I started out being excited by science—but seeing that there weren’t any women scientists—I thought I had no prospects whatsoever,” she tells The New York Times. Her aim, she says, is to be “a good citizen and try to help women and other underrepresented people to fulfill their potential.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!